Mestre-Bach, Gemma
Balodis, Iris M.
Steward, Trevor
Granero, Roser
Fernandez-Aranda, Fernando
Jimenez-Murcia, Susana
Potenza, Marc N.
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA019039)
Connecticut Council on Problem Gambling
FUNCIVA
Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición
Article History
Accepted: 5 March 2022
First Online: 23 March 2022
Declarations
:
: The Yale Human Investigation Committee approved the study (HIC Protocol Number: 0008011937), and signed informed consent was obtained from all participants.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.
: None of the authors have any conflicts of interest. Dr. Potenza has consulted for Opiant Pharmaceuticals, Idorsia Pharmaceuticals, AXA, Game Day Data, and the Addiction Policy Forum; has been involved in a patent application with Yale University and Novartis; has received research support (to Yale) from Mohegan Sun Casino; and has consulted for and/or advised gambling and legal entities on issues related to impulse-control/addictive disorders. Fernando Fernández-Aranda received consultancy honoraria from Novo Nordisk and editorial honoraria as EIC from Wiley. The rest of the authors have no conflicts of interest with the content of this manuscript.